At the 37th Society for Immunotherapy of Cancer Annual Meeting (SITC 2022), set to take place on November 8-12, 2022, in Boston, Massachusetts (United States), via in person/virtual attendance, Antengene will release data from preclinical studies of four pipeline assets, ATG-031, ATG-101, ATG-018, and ATG-027, in one oral presentation and three poster presentations.
SHANGHAI and HONG KONG, Oct. 7, 2022 /PRNewswire/ -- At the 37th Society for Immunotherapy of Cancer Annual Meeting (SITC 2022), set to take place on November 8-12, 2022, in Boston, Massachusetts (United States), via in person/virtual attendance, Antengene will release data from preclinical studies of four pipeline assets, ATG-031, ATG-101, ATG-018, and ATG-027, in one oral presentation and three poster presentations. As the world’s largest and most anticipated gathering in the field of immuno-oncology, the SITC Annual Meeting is designed to promote scientific exchanges and cooperation for improving treatment outcomes for cancer patients.
Details of the oral presentation are shown as below: Title: ATG-031, a first-in-class anti-CD24 antibody, showed potent preclinical anti-tumor efficacy by blocking “don’t-eat-me” signal Details of those three poster presentations are shown below. All posters will be presented at: Title: ATG-101, a tetravalent PD-L1×4-1BB BsAb, demonstrates potent in vivo anti-tumor efficacy in ICI-resistant or refectory mouse tumor models Title: Discovery of blood pharmacodynamic biomarkers for ATR inhibitors Title: ATG-027, a first-in-class B7-H3/PD-L1 bispecific antibody, shows potent T cell activation capability and in vivo anti-tumor efficacy About Antengene Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of “Treating Patients Beyond Borders”. Since 2017, Antengene has built a broad and expanding pipeline of 15 clinical and preclinical assets, of which 10 are global rights assets, and 5 came with rights for Asia Pacific markets including the Greater China region. To date, Antengene has obtained 24 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 6 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor), already approved in mainland China, South Korea, Singapore and Australia. Forward-looking statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled “Risk Factors” in our periodic reports filed with the Hong Kong Stock Exchange and the other risks and uncertainties described in the Company’s Annual Report for year-end December 31, 2021, and subsequent filings with the Hong Kong Stock Exchange. For more information, please contact: Investor Contacts: PR Contacts:
SOURCE Antengene Corporation Limited | ||
Company Codes: HongKong:06996, HongKong:6996 |
View original content to download multimedia:
